Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: N/A
Symbol: NASDAQ:RARE
CUSIP: N/A
Web: www.ultragenyx.com

Capitalization:

Market Cap: $2.31483 billion
Outstanding Shares: 42,458,000

Average Prices:

50 Day Moving Avg: $53.62
200 Day Moving Avg: $59.53
52 Week Range: $49.56 - $91.35

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -7.91
P/E Growth: -0.25

Sales & Book Value:

Annual Revenue: $115,999.00
Price / Sales: 19,567.45
Book Value: $10.12 per share
Price / Book: 5.28

Profitability:

EBITDA: ($280,320,000.00)
Return on Equity: -60.04%
Return on Assets: -52.85%

Debt:

Current Ratio: 6.70%
Quick Ratio: 6.70%

Misc:

Average Volume: 310,466 shs.
Beta: 1.88
Short Ratio: 21.74

Frequently Asked Questions for Ultragenyx Pharmaceutical (NASDAQ:RARE)

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its quarterly earnings results on Thursday, July, 27th. The company reported ($1.72) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.73) by $0.01. During the same quarter in the previous year, the company earned ($1.46) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

When will Ultragenyx Pharmaceutical make its next earnings announcement?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Ultragenyx Pharmaceutical.

Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?

17 analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's stock. Their forecasts range from $55.00 to $90.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $71.94 in the next twelve months. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:

1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (7/18/2017)
2. Cowen and Company analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)
3. Canaccord Genuity analysts commented, "INSM’s Ph3 Arikayce NTM CONVERT trial data is due ~September of this year." (5/8/2017)
4. Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)

Who are some of Ultragenyx Pharmaceutical's key competitors?

Some companies that are related to Ultragenyx Pharmaceutical include Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Sarepta Therapeutics (SRPT), AveXis (AVXS), Spark Therapeutics (ONCE), GW Pharmaceuticals PLC (GWPH), Halozyme Therapeutics (HALO), Array BioPharma (ARRY), Loxo Oncology (LOXO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN), NovoCure Limited (NVCR) and Radius Health (RDUS).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:

Daniel G. Welch, Independent Chairman of the Board
Emil D. Kakkis M.D. Ph.D., President, Chief Executive Officer, Director
Shalini Sharp, Chief Financial Officer, Executive Vice President
Sunil Agarwal M.D., President - Research and Development
Karah Parschauer, Executive Vice President, General Counsel
Jayson Dallas M.D., Chief Commercial Officer and Executive Vice President
Dennis Karl Huang, Chief Technical Operations Officer, Executive Vice President
Thomas Kassberg, Chief Business Officer, Executive Vice President
John R. Pinion II, Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research
William E. Aliski, Independent Director

How do I buy Ultragenyx Pharmaceutical stock?

Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $53.46.

MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)

Community Ranking:		3.7 out of 5 ( )
Outperform Votes:		434 (Vote Outperform)
Underperform Votes:		151 (Vote Underperform)
Total Votes:		585

MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Sell Rating, 8 Hold Ratings, 8 Buy Ratings
Consensus Rating:	Hold (Score: 2.41)
Consensus Price Target:	$71.94 (34.56% upside)

Consensus Price Target History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/6/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$69.00 -> $71.00	N/A
9/19/2017	Robert W. Baird	Reiterated Rating	Buy		Low
9/14/2017	Wedbush	Upgrade	Neutral -> Outperform	$62.00	High
9/12/2017	Canaccord Genuity	Reiterated Rating	Buy		Low
9/6/2017	Barclays PLC	Initiated Coverage	Equal Weight	$60.00	High
8/23/2017	Jefferies Group LLC	Set Price Target	Hold	$62.00	Low
8/23/2017	J P Morgan Chase & Co	Set Price Target	Buy	$87.00 -> $76.00	Low
8/23/2017	JMP Securities	Lower Price Target	Market Outperform	$90.00 -> $80.00	Low
8/23/2017	Stifel Nicolaus	Reiterated Rating	Buy	$95.00 -> $85.00	High
8/23/2017	Leerink Swann	Reiterated Rating	Outperform	$89.00 -> $83.00	High
8/23/2017	Cowen and Company	Reiterated Rating	Outperform		High
8/23/2017	SunTrust Banks, Inc.	Downgrade	Buy -> Hold	$105.00 -> $55.00	High
8/16/2017	Evercore ISI	Initiated Coverage	In -> In-Line	$63.00	High
8/8/2017	HC Wainwright	Reiterated Rating	Neutral -> Neutral	$72.00 -> $75.00	Low
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Market Perform	$72.00	High
3/23/2017	Piper Jaffray Companies	Reiterated Rating	Overweight -> Neutral		High
11/30/2016	Citigroup Inc.	Downgrade	Neutral -> Sell		N/A
9/14/2016	Credit Suisse Group	Reiterated Rating	Buy	$101.00	N/A
6/28/2016	Bank of America Corporation	Initiated Coverage	Buy	$72.00	N/A
2/9/2016	Sterne Agee CRT	Initiated Coverage	Buy		N/A

(Data available from 10/18/2015 forward)

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Earnings History by Quarter for Ultragenyx Pharmaceutical (NASDAQ RARE)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/6/2017		($1.80)					N/A
7/27/2017	Q2 2017	($1.73)	($1.72)	$0.01 million		View	N/A
5/4/2017	Q1 2017	($1.71)	($1.63)	$0.05 million		View	Listen
2/16/2017	Q4 2016	($1.72)	($1.75)	$0.05 million	$0.01 million	View	N/A
11/7/2016	Q3	($1.53)	($1.64)	$7.60 million	$0.11 million	View	Listen
8/8/2016	Q2	($1.44)	($1.46)		$0.02 million	View	N/A
5/9/2016	Q1	($1.29)	($1.35)			View	N/A
2/25/2016	Q4	($1.14)	($1.42)			View	Listen
11/9/2015	Q3	($0.87)	($1.03)			View	N/A
8/13/2015	Q215	($0.63)	($0.83)			View	Listen
5/11/2015	Q1 15	($0.54)	($0.63)			View	Listen
3/25/2015	Q414	($0.53)	($0.52)			View	Listen
11/10/2014	Q314	($0.46)	($0.50)			View	N/A
8/11/2014	Q214	($0.42)	($0.45)			View	N/A
5/12/2014	Q114	($0.37)	($0.85)			View	N/A
3/24/2014		($0.38)	($4.98)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

2017 EPS Consensus Estimate: ($7.23)
2018 EPS Consensus Estimate: ($5.95)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	4	($1.82)	($1.69)	($1.75)
Q2 2017	4	($1.93)	($1.59)	($1.76)
Q3 2017	4	($2.01)	($1.62)	($1.85)
Q4 2017	4	($2.09)	($1.67)	($1.87)
Q1 2018	1	($1.87)	($1.87)	($1.87)
Q2 2018	1	($0.52)	($0.52)	($0.52)
Q3 2018	1	($1.78)	($1.78)	($1.78)
Q4 2018	1	($1.78)	($1.78)	($1.78)

(Data provided by Zacks Investment Research)

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 96.07%

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/28/2017	Emil D Kakkis	CEO	Buy	7,500	$52.52	$393,900.00
5/26/2017	Theodore Alan Huizenga	VP	Sell	480	$57.46	$27,580.80
3/9/2017	Theodore Alan Huizenga	Insider	Sell	2,500	$86.34	$215,850.00
3/2/2017	Shalini Sharp	CFO	Sell	12,000	$90.10	$1,081,200.00
2/27/2017	Shalini Sharp	CFO	Sell	12,000	$80.14	$961,680.00
12/5/2016	William Aliski	Director	Sell	6,000	$78.19	$469,140.00
11/9/2016	Shalini Sharp	CFO	Sell	24,000	$71.20	$1,708,800.00
10/19/2016	Shalini Sharp	CFO	Sell	12,000	$61.40	$736,800.00
10/14/2016	Emil D Kakkis	CEO	Sell	20,000	$63.02	$1,260,400.00
8/15/2016	Emil D Kakkis	CEO	Sell	20,000	$67.61	$1,352,200.00
7/21/2016	Sunil Agarwal	Insider	Sell	649	$52.68	$34,189.32
7/15/2016	Emil D Kakkis	CEO	Sell	20,000	$50.85	$1,017,000.00
6/20/2016	Sunil Agarwal	Insider	Sell	650	$54.16	$35,204.00
5/24/2016	Sunil Agarwal	Insider	Sell	650	$66.00	$42,900.00
5/16/2016	Emil D Kakkis	CEO	Sell	20,000	$59.95	$1,199,000.00
4/20/2016	Sunil Agarwal	Insider	Sell	649	$70.53	$45,773.97
4/15/2016	Emil D Kakkis	CEO	Sell	20,000	$70.33	$1,406,600.00
3/22/2016	Sunil Agarwal	Insider	Sell	650	$61.45	$39,942.50
2/22/2016	Sunil Agarwal	Insider	Sell	658	$63.48	$41,769.84
1/20/2016	Sunil Agarwal	insider	Sell	585	$72.83	$42,605.55
12/31/2015	Emil D. Kakkis	CEO	Sell	20,000	$114.52	$2,290,400.00
12/22/2015	Sunil Agarwal	Insider	Sell	498	$114.81	$57,175.38
12/18/2015	Theodore Alan Huizenga	insider	Sell	1,500	$110.55	$165,825.00
8/20/2015	Sunil Agarwal	insider	Sell	17,020	$111.18	$1,892,283.60
8/12/2015	Thomas Richard Kassberg	SVP	Sell	3,334	$109.70	$365,739.80
7/20/2015	Shalini Sharp	CFO	Sell	3,854	$131.95	$508,535.30
7/8/2015	Thomas Richard Kassberg	SVP	Sell	3,334	$102.12	$340,468.08
6/18/2015	Shalini Sharp	CFO	Sell	4,000	$96.08	$384,320.00
6/17/2015	Theodore Alan Huizenga	Insider	Sell	1,500	$94.80	$142,200.00
6/10/2015	Thomas Richard Kassberg	SVP	Sell	3,334	$88.19	$294,025.46
4/20/2015	Shalini Sharp	CFO	Sell	4,000	$62.23	$248,920.00
4/8/2015	Thomas Richard Kassberg	SVP	Sell	3,333	$58.02	$193,380.66
1/20/2015	Shalini Sharp	CFO	Sell	4,000	$51.24	$204,960.00
12/18/2014	Shalini Sharp	CFO	Sell	4,000	$44.82	$179,280.00
12/10/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$40.22	$134,053.26
12/4/2014	William Aliski	Director	Sell	6,000	$42.16	$252,960.00
11/20/2014	Shalini Sharp	CFO	Sell	4,000	$44.07	$176,280.00
11/12/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$41.85	$139,486.05
10/8/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$53.26	$177,515.58
9/18/2014	Shalini Sharp	CFO	Sell	4,000	$56.00	$224,000.00
9/10/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$54.82	$182,715.06
9/3/2014	Thomas Richard Kassberg	SVP	Sell	20,000	$53.91	$1,078,200.00
8/18/2014	Shalini Sharp	CFO	Sell	4,000	$53.97	$215,880.00
7/14/2014	Group Holdings (Sbs) Advis Tpg	Insider	Sell	488,820	$37.60	$18,379,632.00
1/31/2014	Fmr Llc	Insider	Buy	175,000	$21.00	$3,675,000.00
1/30/2014	Shalini Sharp	CFO	Buy	4,500	$21.00	$94,500.00
1/30/2014	Thomas Richard Kassberg	SVP	Buy	1,500	$21.00	$31,500.00
1/30/2014	William Aliski	Director	Buy	5,000	$21.00	$105,000.00

(Data available from 1/1/2013 forward)

Headline Trends for Ultragenyx Pharmaceutical (NASDAQ:RARE) Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Source:

Date	Headline
	CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes ... - Nasdaq www.nasdaq.com - October 11 at 6:56 AM
	Ultragenyx Pharma (RARE) Says FDA Accepts Burosumab BLA; Sets 04/17/18 PDUFA Date - StreetInsider.com www.streetinsider.com - October 11 at 6:56 AM
	Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application finance.yahoo.com - October 11 at 6:56 AM
	Ultragenyx Pharmaceutical Inc. (RARE) PT Raised to $71.00 at Morgan Stanley www.americanbankingnews.com - October 6 at 11:02 AM
	Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017 finance.yahoo.com - October 6 at 5:42 AM
	Ultragenyx Comments on Dimension Therapeutics' Announcement that Ultragenyx's Offer is a “Superior Proposal” - GlobeNewswire (press release) globenewswire.com - October 3 at 11:26 AM
	Ultragenyx to Acquire Dimension Therapeutics - GlobeNewswire (press release) globenewswire.com - October 3 at 11:26 AM
	Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers finance.yahoo.com - October 3 at 11:26 AM
	Ultragenyx Comments on Dimension Therapeutics’ Announcement that Ultragenyx’s Offer is a “Superior Proposal” www.nasdaq.com - October 2 at 10:05 AM
	Gene Therapy: A Big Week for Many Names finance.yahoo.com - September 25 at 3:32 PM
	Ultragenyx Pharmaceutical Inc. (RARE) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - September 24 at 6:48 AM
	Ultragenyx Pharmaceutical: A Pullback And Upcoming Regulatory Catalysts - Seeking Alpha seekingalpha.com - September 22 at 3:30 PM
	Ultragenyx Pharmaceutical Inc. (RARE) Rating Reiterated by Robert W. Baird www.americanbankingnews.com - September 19 at 3:52 PM
	Brokers Offer Predictions for Ultragenyx Pharmaceutical Inc.'s Q2 2018 Earnings (RARE) www.americanbankingnews.com - September 18 at 5:16 AM
	Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical finance.yahoo.com - September 15 at 3:26 PM
	Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Presents at Baird 2017 Global Healthcare Conference (Transcript) - Seeking Alpha seekingalpha.com - September 15 at 8:01 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Stock Rating Upgraded by Wedbush www.americanbankingnews.com - September 14 at 9:35 AM
	Ultragenyx's Burosumab Positive in Phase II for XLH and TIO - Nasdaq - Nasdaq www.nasdaq.com - September 13 at 3:31 PM
	Ultragenyx's Burosumab Positive in Phase II for XLH and TIO finance.yahoo.com - September 13 at 8:12 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Expected to Post Quarterly Sales of $70,000.00 www.americanbankingnews.com - September 13 at 8:04 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Receives "Buy" Rating from Canaccord Genuity www.americanbankingnews.com - September 12 at 9:28 PM
	Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMR finance.yahoo.com - September 12 at 9:03 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Expected to Post Earnings of -$1.87 Per Share www.americanbankingnews.com - September 11 at 4:36 PM
	Ultragenyx Pharmaceutical Inc. (RARE) Coverage Initiated at Barclays PLC www.americanbankingnews.com - September 10 at 5:16 PM
	Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference finance.yahoo.com - September 7 at 8:06 AM
	Ultragenyx to Present at the Baird 2017 Global Healthcare Conference finance.yahoo.com - August 31 at 9:13 AM
	RARE Disease Concern Appears Undervalued - Seeking Alpha seekingalpha.com - August 30 at 8:27 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - August 30 at 6:46 AM
	Emil D. Kakkis Purchases 7,500 Shares of Ultragenyx Pharmaceutical Inc. (RARE) Stock www.americanbankingnews.com - August 29 at 7:38 PM
	$70,000.00 in Sales Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter www.americanbankingnews.com - August 26 at 7:26 PM
	Jefferies Group Weighs in on Ultragenyx Pharmaceutical Inc.'s FY2018 Earnings (RARE) www.americanbankingnews.com - August 25 at 12:56 PM
	FY2018 EPS Estimates for Ultragenyx Pharmaceutical Inc. (RARE) Reduced by SunTrust Banks www.americanbankingnews.com - August 25 at 12:56 PM
	Ultragenyx Pharma (RARE) Announces Burosumab Data Presentations at ASBMR - StreetInsider.com www.streetinsider.com - August 25 at 10:35 AM
	Q1 2018 EPS Estimates for Ultragenyx Pharmaceutical Inc. Boosted by Analyst (RARE) www.americanbankingnews.com - August 25 at 10:08 AM
	Leerink Swann Weighs in on Ultragenyx Pharmaceutical Inc.'s Q3 2017 Earnings (RARE) www.americanbankingnews.com - August 25 at 8:02 AM
	Comparing Ultragenyx Pharmaceutical (RARE) and Aurinia Pharmaceuticals (AUPH) www.americanbankingnews.com - August 25 at 12:22 AM
	Ultragenyx Pharmaceutical Inc. (RARE) PT Set at $76.00 by J P Morgan Chase & Co www.americanbankingnews.com - August 24 at 7:00 PM
	Ultragenyx Pharmaceutical is Now Oversold (RARE) www.nasdaq.com - August 24 at 11:47 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Sank On Disappointing Study Results www.rttnews.com - August 24 at 11:47 AM
	Ultragenyx Stumbles Over Late-Stage Trial finance.yahoo.com - August 24 at 11:47 AM
	Ultragenyx Discontinues Phase 3 GNE Myopathy Study finance.yahoo.com - August 24 at 11:47 AM
	Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab’s Biologics License Application in the US finance.yahoo.com - August 24 at 11:46 AM
	Ultragenyx Announces Burosumab Data Presentations at ASBMR 2017 Annual Meeting finance.yahoo.com - August 24 at 11:46 AM
	Ultragenyx Pharmaceutical Inc. (RARE) PT Set at $62.00 by Jefferies Group LLC www.americanbankingnews.com - August 24 at 8:46 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Price Target Cut to $80.00 by Analysts at JMP Securities www.americanbankingnews.com - August 23 at 5:57 PM
	Why Omnicom Group Inc. (OMC), Ultragenyx Pharmaceutical Inc (RARE) and Stryker Corporation (SYK) Are 3 of Today’s Worst Stocks investorplace.com - August 23 at 5:08 PM
	Morgan Stanley Reaffirms "Equal Weight" Rating for Ultragenyx Pharmaceutical Inc. (RARE) www.americanbankingnews.com - August 23 at 2:56 PM
	Ultragenyx Pharmaceutical Inc. (RARE) Rating Reiterated by Leerink Swann www.americanbankingnews.com - August 23 at 11:50 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Receives Buy Rating from Stifel Nicolaus www.americanbankingnews.com - August 23 at 11:50 AM
	Ultragenyx Pharmaceutical Inc. (RARE) Earns "Outperform" Rating from Cowen and Company www.americanbankingnews.com - August 23 at 11:10 AM